Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.79 |
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | PKLR | P30613 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536557 | 1.00 | HTR6 (0.79) | HTR6CA2LMNAPKMPKLR | |
| Hydrochloric Acid SCHEMBL3148539 | 0.99 | HTR6 (0.78) | HTR6CA2LMNAPKMPKLR | |
| Hydrochloric Acid SCHEMBL3150087 | 0.99 | HTR6 (0.78) | HTR6CA2LMNAPKMPKLR | |
| SCHEMBL14185674 | 0.89 | HTR6 (0.63) | HTR6CA2LMNAPKMPKLR | |
| SCHEMBL3144794 | 0.89 | HTR6 (0.63) | HTR6CA2LMNAPKMPKLR | |
| SCHEMBL3144218 | 0.89 | HTR6 (1.00) | HTR6CA2LMNAPKMALDH1A1 | |
| SCHEMBL3140329 | 0.89 | HTR6 (1.00) | HTR6CA2LMNAPKMALDH1A1 | |
| SCHEMBL1136455 | 0.89 | HTR6 (1.00) | HTR6CA2LMNAPKMALDH1A1 | |
| SCHEMBL3138990 | 0.88 | HTR6 (0.62) | HTR6CA2LMNAPKMPKLR | |
| SCHEMBL14185678 | 0.88 | HTR6 (0.62) | HTR6CA2LMNAPKMPKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| EP-1748995-B1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | claimed |
| CN-100540546-C | Be used to regulate 5-HT6 acceptor, 5-HT2A acceptor or both aryl sulfonyl benzos two alkane | HOFFMANN LA ROCHE (CH) | 2009-09-16 | — | — | CN | claimed |
| US-7368567-B2 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC (US) | 2008-05-06 | — | — | US | claimed |
| EP-1799306-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-06-27 | — | — | EP | claimed |
| CN-1960983-A | Arylsulfonyl benzodioxanes useful for modulation the 5-HT6 receptor, the 5-HT2areceptor or both | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | claimed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | claimed |
| US-20050250943-A1 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC | 2005-11-10 | — | — | US | claimed |
| EP-2301625-A2 | Compositions and methods for treating cognitive disorders | F. Hoffmann-La Roche AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-7713954-B2 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1748995-B1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | HOFFMANN LA ROCHE (CH) | 2010-02-24 | — | — | EP | disclosed |
| CN-100540546-C | Be used to regulate 5-HT6 acceptor, 5-HT2A acceptor or both aryl sulfonyl benzos two alkane | HOFFMANN LA ROCHE (CH) | 2009-09-16 | — | — | CN | disclosed |
| CN-1960983-A | Arylsulfonyl benzodioxanes useful for modulation the 5-HT6 receptor, the 5-HT2areceptor or both | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | disclosed |
| EP-1748995-A1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | F. Hoffmann-La Roche AG (CH) | 2007-02-07 | — | — | EP | disclosed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | disclosed |
| WO-2005105776-A1 | ARYLSULFONYL BENZODIOXANES USEFUL FOR MODULATION THE 5-HT6 RECEPTOR, THE 5-HT2ARECEPTOR OR BOTH | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250943-A1 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | ROCHE PALO ALTO LLC | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | HTR6, HTR2A, HTR2C | HTR6 1/4885CA2 1600/4885LMNA 3112/4885 |
| US-20050250943-A1 | Arylsulfonyl benzodioxanes, benzoxazines and benzothiazines as 5-HT6 antagonists | HTR6, HTR7, HTR1F | HTR6 1/4885CA2 4115/4885LMNA 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.